Yale Scientist Invents Cosmetic Melanin, Liquid Melanin Moves Closer To Marketplace

February 24, 1998

NEW HAVEN, Conn., Feb. 24, 1998 (Nasdaq: VION)--A collegial conversation over a research laboratory bench, the image of a natural-looking tan, some transformational chemistry, and a commitment to protect people from the sun's harmful ultraviolet rays have proven to be a winning combination for a Yale University School of Medicine scientist.

John M. Pawelek, Ph.D., a senior research scientist in the department of dermatology at the Yale School of Medicine, recently was awarded a U.S. patent entitled Cosmetic Melanins for producing and composing synthetic melanins that may be used in cosmetic products.

Through its Office of Cooperative Research, Yale licensed the Melasyn technology originating in a medical school laboratory to Vion Pharmaceuticals, Inc. of New Haven. This month, Vion announced an exclusive world-wide licensing agreement with San-Mar Laboratories of Elmsford, NY., to manufacture and market products containing Melasyn.

Throughout nature, melanin is used in such diverse areas as protection from ultraviolet radiation, camouflage and species recognition. It is insoluble and difficult to work with, making it impractical for inclusion in creams and lotions. "But we have invented simple methods for creating melanin substitutes that dissolve readily in water and, when incorporated into cosmetic creams, can be spread evenly on the skin to instantly produce a tan," Dr. Pawelek states.

In inventing this unique product, Dr. Pawelek employed one of scientists' historical approaches to research: self-experimentation. "For nearly four years, I have been applying the material daily to my own face, and it produces such a natural-looking tan that it even surprises my dermatologist colleagues at Yale," he quips. "Scarcely a day goes by when someone on an elevator or in a hallway doesn't ask me where I was on vacation."

The ingredients make all the difference. "As one of our starting materials, we use the active ingredient of the aloe vera plant," the scientist says. "When this substance is transformed into melanin, it generates a water-soluble product and a lustrous tan."

The Yale laboratory work behind the patenting and licensing offers interesting insight into the process of research and development of potential new products. "It started several years ago with our basic research on skin enzymes that produce melanin," Dr. Pawelek explains. "Melanin usually is insoluble in water and forms a gummy solid in test tubes. One day, however, we noticed that the melanin in one enzyme assay remained dissolved in water," he recalls.

Dr. Pawelek credits his colleague, Jean Bolognia, M.D., who conducts her research in his laboratory, with the idea for cosmetic use of melanin. If the melanin were really soluble, she surmised, it should be useful as a cosmetic. "From that point on," he says, "we began a search for the right combination of ingredients and methods to produce cosmetic melanin.

"We were motivated by the thought that melanin naturally protects our skin from cancer induced by ultraviolet light. Perhaps, we reasoned, synthetic melanin would do the same," he says. "If we could design a melanin that produced a natural-appearing tan, we believed that people might be attracted to the product through its cosmetic qualities and simultaneously apply a sun-protectant, affording them added sun protection and potentially reducing the incidence of sun-induced skin cancer," hopes Dr. Pawelek, a cancer biologist who studies melanoma. Skin cancers are the most prevalent type of cancer in the world, so even a small reduction in their incidence would make an impact on a significant number of people.

"We have, in fact, shown that Melasyn protects the skin of mice from ultraviolet light," he notes. "Now, controlled clinical studies are needed in order to be able to claim its protective effects in humans, and those will take months. In the meantime, we hope that its excellence as a cosmetic self-tanner will be sufficient to promote use."

Frank Penna, executive vice president of San-Mar Laboratories, states, "We are very excited about the Melasyn technology. Its potential applications are quite varied, from cosmetics to sunscreens." San-Mar intends to aggressively pursue commercial development.

The Melasyn technology grew out of Vion's cancer research collaborations with Dr. Pawelek and his Yale colleagues. This same group discovered Vion's TAPET (tumor amplified protein expression therapy), which potentially uses a genetically engineered strain of the Salmonella bacteria to target cancerous tumors and eventually inhibit tumor growth.
-end-


Yale University School of Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.